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ciprofloxacin, temafloxacin, doxycycline, ceftriaxone, and spectinomycin by using an agar dilution method.
Tosufloxacin was as active as temafloxacin against C. trachomatis (MIC for 90% of strains tested [MIC90], 0.25 ,ug/ml; MBC for 90% of strains tested [MBC90], 0.25 ,ug/ml) and was almost as active as doxycycline (MIC90, 0.06 ,ug/ml; MBC90, 0.125 ,ug/ml). Ciprofloxacin, temafloxacin, and tosufloxacin were extremely active against N. gonorrhoeae, including spectinomycin-resistant N. gonorrhoeae and penicillinase-producing N. gonorrhoeae, with MIC90s of 0.004, 0.015, and 0.008 ,g/ml, respectively. Ceftriaxone was slightly less active (MIC90, 0.03 ,ug/ml), and doxycycline was the least active drug tested (MIC90, 4 .0 ,ug/ml). Tosufloxacin and temafloxacin had excellent activity against the C. trachomatis and N. gonorrhoeae strains tested.
Tosufloxacin is a new aryl-fluoronaphthyridine antimicrobial agent with potent in vitro activity against aerobic and anaerobic bacteria (1, (4) (5) (6) . Other quinolones have been shown to have in vitro and in vivo activity against Chlamydia trachomatis and Neisseria gonorrhoeae (6, 8) . Since there are limited data on the activity of this drug against C. trachomatis and spectinomycin-resistant N. gonorrhoeae
MATERIALS AND METHODS
Tosufloxacin and temafloxacin (Abbott Laboratories, North Chicago, Ill.), ceftriaxone (Roche Diagnostics, Div. Hoffmann-La Roche Inc., Nutley, N.J.), ciprofloxacin (Miles Pharmaceuticals, West Haven, Conn.), and doxycycline and spectinomycin (Sigma Chemical Co., St. Louis, The antimicrobial susceptibility of C. trachomatis was determined by using 96-well microdilution plates as previously described (9) . Briefly, 24-h-old McCoy cell monolayers grown in antibiotic-free medium were inoculated with the dilution of the C. trachomatis test strain known to yield 100 to 1,000 inclusions per well. The plates were centrifuged at 1,000 x g at 24°C for 60 min and then overlaid with 0.1 ml of each drug solution to yield appropriate twofold dilutions. Each solution was tested in triplicate. Antibiotic-free controls were included on each plate. Cultures were incubated for 48 h at 37°C in 5% CO2, fixed with absolute ethanol, and stained with fluorescein-conjugated mouse monoclonal antibody to C. trachomatis (Ortho Diagnostics, Inc., Raritan, N.J.) according to the directions of the manufacturer. The MIC was defined as the lowest concentration of antibiotic without inclusions. The MBC was defined as the lowest concentration of antibiotic yielding no inclusions after passage onto 24-h-old McCoy cell monolayers grown in antibiotic-free medium.
In vitro susceptibility testing of N. gonorrhoeae was performed by using an agar dilution method with a GC agar base (Difco Laboratories, Detroit, Mich.) supplemented with 1% hemoglobin and 1% IsoVitaleX (BBL Microbiology Systems, Cockeysville, Md.). Plates were read after 24 h of incubation at 35°C in an increased CO2 atmosphere. Penicillinase production was determined by the nitrocefin dish method according to the directions of the manufacturer (BBL).
RESULTS
Results of the C. trachomatis antimicrobial susceptibility testing are shown in Table 1 Tables 2 and 3 . Ciprofloxacin, temafloxacin, and tosufloxacin were extremely active against both SRNG and PPNG. Ceftriaxone was slightly less active than the quinolones, with a MIC90 of 0.03 pug/ml for both SRNG and PPNG.
Doxycycline displayed limited activity against PPNG and SRNG (MIC90, 4.0 pug/ml). DISCUSSION The in vitro activity of tosufloxacin against C. trachomatis was recently reported by Maeda et al. (7) . Our results indicate that tosufloxacin is as active against C. trachomatis from our geographic area as it is against C. trachomatis from Japan. The MICs and MBCs of temafloxacin and ciprofloxacin that we report are comparable to those obtained by other investigators (7) (8) (9) . There is no published information on the activity of tosufloxacin against SRNG. Although less common than PPNG, SRNG has become increasingly frequent in some parts of the world (2). Our results indicate that tosufloxacin is more active than ceftriaxone against this type of N. gonorrhoeae and also more active than ceftriaxone against PPNG.
While some studies of the clinical use of ciprofloxacin in genital chlamydial infection have been disappointing, other studies have been encouraging (3, 8) . Since concentrations of tosufloxacin in serum vary from 0.4 to 0.8 gxg/ml when a dose of 150 mg twice daily is administered, sufficient distribution of the drug to eradicate C. trachomatis would be expected and clinical trials are warranted (7) . The excellent in vitro activity of tosufloxacin against N. gonorrhoeae, including SRNG and PPNG strains, indicates that this drug may be as active as other quinolones in the treatment of genital gonococcal infections. Since a significant number of people with cervicitis and urethritis are concomitantly infected with C. trachomatis and N. gonorrhoeae, tosufloxacin may have a role as monotherapy for these patients.
